Fig. 1From: Target occupancy study and whole-body dosimetry with a MAGL PET ligand [11C]PF-06809247 in non-human primatesRepresentative MRI and PET summation images (0–63 min) of [11C]PF-06809247 at baseline and following pretreatment with a selective MAGL inhibitor (NHP4; 0.42 mg/kg)Back to article page